Blockbuster drugs face a massive patent cliff in 2026 Generic and biosimilar competition is poised to disrupt billions in annual drug sales, reshaping market dynamics for some of the industry’s most important medicines.

https://www.drugdiscoverynews.com/blockbuster-drugs-face-a-massive-patent-cliff-in-2026-17019?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_8FpRA_clew71NPJmVat5rbxixpCI0Md-EB1dhkQKKfSzev0alK-lbF0ggSI-7uEbMWJsrU5qONEcy5mH3ES7wCMiNMQ&_hsmi=405284917&utm_content=405284917&utm_source=hs_email In the world of pharmaceuticals, patents matter. They grant drugmakers exclusive rights to sell a medicine for a defined period, allowing companies to recover massive research and development costs and, in many cases, generate profits to fund future innovation. Once those patents expire, however, the competitive landscape shifts dramatically as cheaper generic or biosimilar versions can enter the market, often leading to steep price reductions and sharply reduced revenue for the original brand.